Dr. Agarwal's Health Care Plans Delhi NCR Expansion To Strengthen Leadership Over 2-3 Years

Market snapshot: Dr. Agarwal's Health Care Limited has formally announced aggressive expansion plans in the highly competitive Delhi NCR region over the next two to three years. According to its latest FY26 Annual Report, the company is looking to build a dominant leadership position in the region, anchored by clinical excellence and a proven hub-and-spoke healthcare delivery model. This strategic push is already reflecting in strong regional volumes and revenue acceleration in the northern zone.

Data Snapshot

• Consolidated sales rose 25.97% YoY to ₹614.02 crore in Q1 FY27 from ₹487.42 crore in Q1 FY26.
• Consolidated net profit surged 50.52% YoY to ₹45.23 crore in Q1 FY27 from ₹30.05 crore in Q1 FY26.
• North region revenue expanded 50.5% YoY to ₹57 crore in Q1 FY27, contributing 9% of group revenues.

What's Changed

• The company's entry into Delhi NCR commenced in mid-2025, establishing 7 facilities by the end of FY26.
• In Q1 FY27, active facilities in the NCR region grew to 8, following the addition of branches in Faridabad, Shahdara, and Ghaziabad.
• The company plans to add another 3 to 5 facilities in Delhi NCR during the remainder of the current fiscal year.

Key Takeaways

• Aggressive regional focus in Delhi NCR is driving rapid market capture, backed by high patient traction and surgical volumes.
• Stellar operational performance is supported by same-store sales growth and an increasing shift toward high-end premium procedures.
• The pending merger of Dr. Agarwal's Eye Hospital Limited with Dr. Agarwal's Health Care Limited is set to simplify the corporate structure.

SAHI Perspective

The company's aggressive, organic-led expansion in Delhi NCR is successfully diversifying its revenue base away from its historic reliance on Southern markets. By employing a disciplined hub-and-spoke model, Dr. Agarwal's is capturing market share in the premium surgical segment, showcasing that its clinical and operational playbook is highly replicable across diverse healthcare clusters in India.

Market Implications

The rapid scale-up in a premium, high-margin healthcare segment like ophthalmology is expected to drive long-term operating leverage. While greenfield expansion incurs near-term setup and doctor onboarding costs, the quick maturation of these facilities bodes well for consolidated margins. Investors should monitor regional volume trends as the newly opened NCR clinics scale toward mature performance.

Trading Signals

Market Bias: Bullish

Solid organic expansion and regional market capture in Delhi NCR are backed by a strong Q1 FY27 financial performance, with revenues growing 25.97% YoY to ₹614.02 crore and net profits expanding 50.52% YoY to ₹45.23 crore. The upcoming corporate merger also serves as a strong operational catalyst.

Overweight: Healthcare Facilities, Specialised Ophthalmology Services

Trigger Factors:

• MATURATION SPEED: Rate at which new Delhi NCR facilities achieve operational break-even
• PREMIUM MIX SHIFT: Growth in higher-end procedures like Femto cataract and refractive surgeries
• MERGER TIMELINE: Execution and integration of the listed entity merger by mid-November 2026

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian eye care services market continues to show strong structural tailwinds, driven by an aging demographic and increasing demand for surgical vision correction. Organized hospital chains are leading this transition, leveraging hub-and-spoke models and high-end technological capabilities to outpace fragmented clinics.

Key Risks to Watch

• Ramp-up losses associated with aggressive greenfield center openings in competitive metro markets
• Talent acquisition challenges and doctor attrition, though senior doctor attrition remains low at 2-3%
• Stiff competition from other organized eye care networks and multi-specialty hospitals in Delhi NCR

Recent Developments

During August 2026, the company witnessed a major block deal where key private equity investors TPG and Temasek collectively offloaded nearly a 13% stake in the firm for ₹2,008 crore to domestic institutional investors. Additionally, the company reported a stellar financial performance for Q1 FY27, with consolidated revenues reaching ₹614.02 crore and net profit increasing by 50.52% year-on-year to ₹45.23 crore.

Closing Insight

Dr. Agarwal's Health Care's disciplined execution and regional diversification are shaping a strong growth vector. By rapidly scaling its Delhi NCR footprint alongside healthy corporate consolidation, the firm is well-positioned to achieve sustainable, pan-India leadership.

High Performance Trading with SAHI.